Dr. Art Rastinehad, DO, has been recognized as a 2026 Castle Connolly Top Doctor, marking his 12th year receiving this honor. Only 7 percent of licensed physicians nationwide are selected annually for this designation, which is based on peer nominations and review by the Castle Connolly research team. Dr. Rastinehad serves as professor of urology and radiology, vice chair of urology at Northwell's Lenox Hill Hospital, and Northwell Health System director for prostate cancer.
The recognition reflects Dr. Rastinehad's contributions to precision prostate care, which emphasizes matching each patient with tailored diagnostic and treatment options. His clinical and research focus includes MRI-targeted biopsy, focal therapy, image-guided treatment, and prostate artery embolization for enlarged prostate or BPH. He was the first dual fellowship-trained urologic oncologist and interventional radiologist, completing advanced training through the National Institutes of Health, the National Cancer Institute, and Northwell's North Shore University Hospital.
Key achievements include early validation of MR/US fusion biopsy in the United States, publishing the first series on prostate artery embolization in 2006, and serving as principal investigator in developing UroNav/Philips MR/US fusion technology for prostate biopsy and focal therapy planning. He is also a founding executive board member of the Focal Therapy Society and has over 20 years of experience in interventional urology.
Dr. Rastinehad stated, "Being recognized as a Castle Connolly Top Doctor is meaningful because it reflects the trust patients and peers place in our work. My goal is to help men make clear, informed decisions about prostate cancer, enlarged prostate, and urinary symptoms by coordinating the right evaluation and the most appropriate treatment options for each individual patient."
His practice at the urology department at Lenox Hill Hospital provides advanced prostate care for men with elevated PSA, abnormal prostate MRI, localized prostate cancer, BPH, and complex treatment decisions. The Castle Connolly selection process considers medical education, training, hospital appointments, and disciplinary histories; doctors cannot pay to be selected.
This announcement matters because it signals the growing importance of precision medicine in urology, moving away from standardized protocols toward individualized care that improves outcomes and reduces unnecessary treatments. Dr. Rastinehad's work, highlighted by this recognition, influences how prostate cancer and BPH are diagnosed and managed, potentially setting new standards for patient-centered care in the New York metro area and beyond.
